NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Trellis Bioscience

Trellis Bioscience

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://trellisbio.com/

Last Round

Series C

Jul 16, 2026

Total Funding Raised

$26.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Trellis Bioscience is a biotechnology company that develops native human monoclonal antibody therapies for infectious diseases and cancer using its proprietary CellSpot™ discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

monoclonal antibodiesmAbsantibody discoveryCellSpot platformbacterial biofilmsanti-biofilmantibiotic resistanceinfectious disease treatmentsingle-cell antibody discoveryfully human antibodiesclinical stage biotechprosthetic joint infectiononcologyCARB-X

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Trellis Bioscience Comparables

Compare Trellis Bioscience with similar companies based on industry and business-model similarity.

Trellis Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Peptilogics
80%
Aridis Pharmaceuticals, Inc.
79%
Clarametyx Biosciences
77%

Trellis Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJul 16, 2026
Series CMay 15, 2026
VC RoundOct 22, 2024
GrantJul 18, 2024
GrantJan 14, 2020
Grant
Aug 16, 2012

Key People

Founding team and executive leadership

Brian Cunningham

CEO

Executive Team

Stefan Ryser

President & CEO

Executive Team

Bruce Keyt

Chief Technology Officer

Executive Team

Trellis Bioscience Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2026

    $9M round led by Easton-Hunt Capital Partners.

  • May 15, 2026

    $6.1M raised in Seed Round.

Trellis Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Trellis Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Trellis Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedwood City, California
Employee Range17
Year Founded1998
Last FundingJul 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.